Effect of Fat Composition in Enteral Nutrition for Crohn's Disease in Adults: A Systematic Review
Authors
Affiliations
Background & Aims: The role of enteral nutrition (EN) fat composition in regulating inflammation in Crohn's disease (CD) is not clear. There is, moreover, insufficient evidence to guide the choice of EN in CD with any confidence. We have reanalysed the findings of previous studies in a systematic review focussing on the relationship between EN fat content and remission rates (RR).
Methods: A systematic search with no language restriction was undertaken in Medline and Embase databases supplemented by a manual search in the reference lists of identified studies. The selection criteria were: clinical trial, exclusive EN, adults and CD. Data on the type of EN, its fat composition, achieved RR, and study design were extracted. An established assessment tool was used to assess the quality of the studies.
Results: A total of 29 clinical trials are included in this review. The quality of the studies was highly variable. No fewer than 27 formulations of enteral feed were identified including 4 elemental and 23 non-elemental preparations. There was a positive correlation between the total n-6 fatty acid content and response rates, which was significant when expressed as the ratio between n-6 and n-3 fatty acids (r = 0.378, p = 0.018). A non-significant positive trend was founded (r = 0.072; p = 0.643) between medium chain triglycerides (MCT) delivery as a percentage of the total energy provision and RR. While a non-significant negative trend was reported for the delivery of monounsaturated fatty acids (MUFA) (r = -0.23, p = 0.13). A qualitative advantage to regimens based on safflower oil suggest that optimised therapeutic approaches are within reach.
Revolution in diet therapy for inflammatory bowel disease.
Melton S, Day A, Bryant R, Halmos E JGH Open. 2024; 8(7):e13097.
PMID: 38957480 PMC: 11217770. DOI: 10.1002/jgh3.13097.
Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment.
Yan D, Ye S, He Y, Wang S, Xiao Y, Xiang X Front Immunol. 2023; 14:1286667.
PMID: 37868958 PMC: 10585177. DOI: 10.3389/fimmu.2023.1286667.
Su H, Tan Y, Zhou Z, Wang C, Chen W, Wang J Exp Ther Med. 2023; 26(2):369.
PMID: 37415840 PMC: 10320654. DOI: 10.3892/etm.2023.12068.
Jimenez-Sanchez A, Martinez-Ortega A, Remon-Ruiz P, Pinar-Gutierrez A, Pereira-Cunill J, Garcia-Luna P Nutrients. 2022; 14(7).
PMID: 35406067 PMC: 9003415. DOI: 10.3390/nu14071440.
The Management of the Hospitalized Ulcerative Colitis Patient, the Medical-Surgical Conundrum.
Carvello M, Watfah J, Spinelli A Curr Gastroenterol Rep. 2021; 23(12):25.
PMID: 34716521 DOI: 10.1007/s11894-021-00820-7.